10-K: Xenetic Biosciences Reports Reduced Losses, Advances DNase Oncology Program

Xenetic Biosciences, Inc. reported a significant reduction in net loss for 2025, driven by increased royalty revenue and a successful $4.0 million public offering, as it continues to advance its proprietary DNase technology for solid tumors.

Summary

• Net loss for the year ended December 31, 2025, decreased by 32.3% to approximately $2.7 million, compared to $4.0 million in 2024.
• Total revenue increased by 19.0% to approximately $3.0 million in 2025, up from $2.5 million in 2024, primarily due to higher royalty revenue from a sublicense agreement with Takeda.
• Research and development (R&D) expenses decreased by 6.8% to $3.1 million in 2025, from $3.3 million in 2024, largely due to a $0.7 million impairment charge in 2024 that did not recur.
• Excluding the 2024 impairment charge, adjusted R&D expenses increased by 18.6% to $3.1 million in 2025, reflecting increased consulting, preclinical, and manufacturing development efforts for the DNase program.
• General and administrative expenses decreased by 19.6% to approximately $2.7 million in 2025, from $3.4 million in 2024, mainly due to severance and benefits paid to former executives in 2024.
• Cash and cash equivalents stood at approximately $7.9 million as of December 31, 2025, an increase from $6.2 million at the end of 2024.
• The company successfully completed an underwritten public offering in October 2025, raising net proceeds of approximately $4.0 million.
• A formal strategic review process is underway to maximize shareholder value, considering options such as a sale, asset sale, or business combination.
• The systemic DNase program is being advanced into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors, including colorectal cancer (CRC).
• Exploratory studies of systemic DNase I in combination with Folfirinox for pancreatic cancer and with anti-CD19 CAR T cells for large B cell lymphoma are being conducted in Israel through a collaboration with PeriNess Ltd.
• Collaborations with Scripps Research and the University of Virginia (UVA) continue to advance preclinical and translational development of the DNase technology, with additional funding committed for ongoing research.
• The company's PolyXen platform continues to generate royalty payments from Takeda, but active internal development efforts for PolyXen and XCART have ceased, with focus shifted to DNase technology.
• The 2025 Annual Meeting of Stockholders was adjourned multiple times due to a lack of a requisite quorum, with a new date yet to be determined.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing with a moderately positive sentiment. The significant reduction in net loss, increased revenue, and successful capital raise are strong positives for a clinical-stage company. However, the ongoing strategic review and continued reliance on external funding for long-term goals introduce a degree of uncertainty.

Positives

• Net loss significantly decreased by 32.3% to $2.7 million in 2025, indicating improved financial performance compared to the prior year.
• Royalty revenue increased by 19.0% to $3.0 million in 2025, demonstrating continued income generation from the PolyXen sublicense with Takeda.
• A successful underwritten public offering in October 2025 raised approximately $4.0 million in net proceeds, strengthening the company's cash position and liquidity.
• Cash and working capital increased, providing a stronger financial foundation for ongoing operations and development.
• The company is actively advancing its systemic DNase program into clinical studies for high-unmet-need oncology indications like pancreatic cancer and colorectal cancer.
• Preclinical development for DNase-armored CAR T program has been completed, and mechanism-of-action and translational studies are advancing.
• New exploratory clinical studies for DNase I in pancreatic cancer and large B cell lymphoma have commenced in Israel through a collaboration with PeriNess Ltd.
• Ongoing research collaborations with Scripps Research and the University of Virginia are expanding the scope of work and receiving additional funding, indicating continued scientific progress.

Negatives

• The company has never been profitable and reported an accumulated deficit of approximately $199.9 million as of December 31, 2025.
• Interest income decreased by 40.8% to $148,000 in 2025, primarily due to lower average invested funds.
• The 2025 Annual Meeting of Stockholders was repeatedly adjourned due to a lack of a requisite quorum, which could indicate shareholder disengagement or governance challenges.
• The company is highly dependent on the success of its early-stage DNase technology, with no other drug candidates having received regulatory marketing authorization.
• Active development efforts for legacy technologies like XCART and PolyXen have ceased, narrowing the pipeline focus.
• The strategic review process introduces uncertainty regarding the company's future structure and operations, with no assurance of a successful transaction.
• The company relies heavily on third parties for manufacturing, clinical studies, sales, marketing, and distribution, which introduces operational risks and potential conflicts of interest.

Risks

• The outcome and timing of the strategic review process are uncertain, and the Board may decide not to undertake a strategic alternative, potentially disrupting the business and adversely affecting stock price.
• The company has never been profitable and requires substantial additional funding to achieve its goals; failure to obtain necessary capital may force delays or termination of product development.
• Raising additional capital may cause dilution to stockholders, restrict operations, or require relinquishing rights to technologies or drug candidates.
• There is a risk of not continuing to meet Nasdaq listing requirements, which could result in delisting of common shares.
• The business is substantially dependent on the success of the DNase technology, and there are no assurances that competing technologies would not harm business development.
• As an early-stage company, business operations may never fully materialize and create value for investors due to the inherent uncertainty of pharmaceutical product development.
• Conflicts may arise between the company and its collaborators or strategic partners, potentially limiting the ability to implement strategies or causing partners to act in their self-interest.
• Reliance on third parties to conduct, supervise, and monitor clinical studies carries the risk of unsatisfactory performance, which could harm the business.
• Collaborators or strategic partners may adopt alternative technologies or be unable to develop commercially viable products with the company's technology, negatively impacting revenues.
• Difficulty in enrolling patients in clinical studies could delay or prevent clinical trials of pharmaceutical products.
• Substantial delays in commencement, enrollment, or completion of clinical trials, or failure to demonstrate safety and efficacy, could prevent timely commercialization.
• Regulatory approval for drug candidates is uncertain and may be for a more narrow indication than expected, or may never be obtained.
• Even if regulatory approval is obtained, drug candidates will remain subject to extensive ongoing regulatory scrutiny and requirements.
• Commercial success depends on market acceptance by physicians, patients, and third-party payors, which is not guaranteed.
• The commercial potential of a pharmaceutical candidate is difficult to predict, and a smaller-than-anticipated market size could negatively impact revenue.
• Failure to obtain or maintain adequate coverage and reimbursement for approved drug candidates could limit marketing ability and decrease revenue generation.
• Limited resources may lead to pursuing less profitable research programs or drug candidates, foregoing more successful opportunities.
• Failure to adequately protect or enforce intellectual property rights, or challenges to issued patents, could impair the ability to operate effectively.
• Infringement on the intellectual property rights of others could adversely affect business and profitability.
• Failure to comply with obligations in intellectual property license agreements could result in loss of critical license rights.
• Claims that employees, consultants, or contractors have wrongfully used or disclosed confidential information of third parties could lead to litigation and adverse impacts.
• Claims challenging the inventorship or ownership of patents and other intellectual property could result in loss of valuable rights.
• Inability to protect confidential information and trade secrets would harm the business and competitive position.
• Future success depends on the ability to retain principal members of the executive team, consultants, and advisors, and to attract and motivate qualified personnel.
• Expanding the organization may lead to difficulties in managing growth, disrupting operations.
• The market price of securities may be highly volatile, and actions of activist shareholders could incur substantial costs and divert management's attention.
• Preferred stockholders have preferential rights that could differ from common stockholders' interests and cause dilution.
• Potential product liability claims could result in substantial liability and costs.
• Unfavorable U.S. or global economic conditions, including geopolitical events and conflicts, could negatively affect financial condition and operations.
• The ability to use potential future operating losses and net operating loss (NOL) carryforwards to offset taxable income could be limited by Section 382 of the U.S. Internal Revenue Code.
• Governments may impose price controls, adversely affecting future profitability.
• Misconduct by employees, principal investigators, consultants, and commercial partners could lead to non-compliance with regulations and legal actions.
• Use of drug candidates could be associated with adverse side effects, potentially halting development or leading to product liability lawsuits.
• Failure to comply with environmental, health, and safety laws and regulations could result in fines or penalties.
• Non-cash charges, such as share-based payments, may adversely impact results of operations.
• Varying interpretations of accounting standards may cause restatements of previously reported results.
• Failure in information technology systems or cybersecurity attacks could significantly disrupt operations.

Future Outlook

The company's primary focus is to advance its systemic DNase program into the clinic as an adjunctive therapy for pancreatic cancer and other locally advanced or metastatic solid tumors, including colorectal cancer. It intends to pursue industry collaborations and potential licenses for DNase, as well as orphan drug designations and accelerated approval pathways. Continuous pipeline growth and advancement of out-licensed drug candidates are dependent on raising sufficient capital and entering into new strategic arrangements. The company believes its existing resources will be adequate to fund operations for at least twelve months but anticipates needing additional capital in the long-term to pursue business initiatives.

Management Comments

• We are a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers.
• Our proprietary DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs).
• We are focused on advancing the development of our DNase technology toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors.
• We have initiated a formal strategic review process with the assistance of outside financial and legal advisors, considering a wide range of alternatives to maximize shareholder value.
• We remain committed to advancing our DNase technology and do not intend to make further announcements regarding the review process unless and until the Board approves a specific transaction or otherwise determines that further disclosure is appropriate.
• We believe that our existing resources will be adequate to fund our operations for a period of at least twelve months from the date of the issuance of these financial statements.
• We anticipate we will need additional capital in the long-term to pursue our business initiatives.

Industry Context

StockSavvy.ai notes that Xenetic Biosciences operates in the highly competitive and rapidly evolving immuno-oncology and biopharmaceutical sectors. The company's focus on DNase technology targeting NETs for solid tumors, particularly pancreatic and colorectal cancers, addresses areas with significant unmet medical needs and high mortality rates. While the market for oncology treatments is large and growing, it is also characterized by numerous well-resourced competitors. The shift away from active development of legacy platforms like PolyXen and XCART to concentrate resources on DNase reflects a common industry strategy for early-stage companies to streamline pipelines and focus on their most promising assets. The pursuit of orphan drug designations and accelerated approval pathways aligns with industry trends to expedite development for rare or severe conditions. The reliance on collaborations with academic institutions and CROs is a standard capital-efficient model for preclinical and clinical development in the biotech space.

Management Changes

Corporate Governance

Legal Proceedings

• As of December 31, 2025, there are no matters that, in the opinion of management, might have a material adverse effect on the company's financial position, results of operations, or cash flows.

Related Party Transactions

• The company has ongoing research, development, license, and supply agreements with PJSC Pharmsynthez, a related party that holds approximately 2.3% of total outstanding common stock and all outstanding Series B Preferred Stock as of December 31, 2025.
• A clinical trial services agreement was entered into with PeriNess Ltd. in Q4 2024, where Director Dr. Dmitry Genkin is a significant shareholder and Mr. Moshe Mizrahy is a majority shareholder and director. Expenses of approximately $123,000 were incurred in 2025.
• A Consulting Agreement was entered into with Dr. Dmitry Genkin, Chairman of the Board, effective January 1, 2025, for services related to the DNase-based oncology program. Approximately $0.4 million was paid to Dr. Genkin in 2025, and the agreement was extended through December 31, 2026.

Stakeholder Impact

• Shareholders: Potential for value maximization through the strategic review process, but also risk of dilution from future capital raises and volatility in stock price. The repeated adjournment of the annual meeting may indicate challenges in shareholder engagement.
• Employees: The company has a small team of two full-time employees, supplemented by consultants. Future growth plans will require expansion, which could impact existing personnel and operations.
• Customers/Patients: The advancement of DNase technology aims to provide new therapeutic options for difficult-to-treat cancers like pancreatic and colorectal carcinoma, addressing significant unmet medical needs.
• Collaborators/Partners: Ongoing collaborations with Takeda, Scripps Research, UVA, and PeriNess are crucial for product development and revenue generation, but conflicts or underperformance by partners could impact the company's strategy.
• Creditors: The company's improved cash position and successful capital raise enhance its ability to meet short-term obligations, but long-term funding needs remain.

Next Steps

• Advance the systemic DNase program into a first-in-human, multicenter, dose escalation and dose-expansion study for locally advanced or metastatic solid tumors.
• Continue preclinical research to demonstrate the effectiveness of DNase-armored CAR T cells against solid tumor indications.
• Pursue industry collaborations and potential licenses to develop DNase for other uses and indications.
• Seek orphan drug designations and accelerated approval pathways for relevant oncology indications in the U.S. and Europe.
• Reconvene the 2025 Annual Meeting of Stockholders at a new date and time to achieve a requisite quorum.
• Continue discussions with the University of Virginia concerning completion of current activities and potential expansion of the scope of work under the UVA Agreement.
• Await further feedback from regulatory authorities regarding Pharmsynthez's registration dossier for ErepoXen in Russia.

Key Dates

Recommendation

Xenetic Biosciences is in a transitional phase, marked by a strategic review and a concentrated focus on its DNase technology. While the company demonstrated improved financial performance in 2025 with reduced net losses and increased royalty revenue, coupled with a successful capital raise, it remains an early-stage biopharmaceutical company with no approved products and a substantial accumulated deficit. The ongoing strategic review introduces significant uncertainty regarding the company's future structure and direction. For a seasoned investor, the potential upside from the DNase program's clinical advancement is balanced by the high risks inherent in drug development, competitive landscape, and the unresolved strategic alternatives. A 'hold' recommendation acknowledges the positive financial trends and clinical progress while advising caution due to the speculative nature of its pipeline and the strategic uncertainties.

Keywords

DNase technology, Immuno-oncology, Pancreatic cancer, Colorectal cancer, Solid tumors, Neutrophil extracellular traps (NETs), CAR T cell therapy, Biopharmaceutical, SEC filing, 10-K, Clinical stage, Strategic review, Capital raise, Royalty revenue, Research and development, Drug development, Biotechnology, PolyXen platform